Omnigraft™ Dermal Regeneration Matrix was Recognized as a Top Ten Innovation by Podiatry Today

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that its recently introduced product, Integra® Omnigraft™ Dermal Regeneration Matrix, has been recognized by Podiatry Today as one of the "Top Ten Innovations in Podiatry" in 2016.  Podiatry Today is an award-winning, premier publication that emphasizes informative clinical features and practice management articles.  Annually, Podiatry Today picks the most innovative products in the podiatric industry to showcase in their monthly publication.

In the article, Dr. Paul Kim, an Associate Professor and the Director of Research for the Department of Plastic Surgery at Georgetown, noted that Omnigraft was the subject of the largest multicenter randomized controlled trial to date on diabetic foot ulcers, with reported median time to complete DFU closure of 43 days in comparison to 78 days for patients treated with standard of care alone.  The full article is available at http://www.podiatrytoday.com/node.

Omnigraft was launched in May of 2016 and was featured at the American Podiatric Medical Association (APMA) 2016 Annual Scientific Meeting (The National) held in Philadelphia from July 14 — 17. APMA is a nationally recognized organization representing a majority of the estimated 15,000 podiatrists nationwide.  In addition to Omnigraft, Integra featured PriMatrix® Dermal Repair Matrix, PriMatrix® Ag Antimicrobial Dermal Repair Matrix and VolTAC™ Antimicrobial Wound Dressing. Collectively, Omnigraft, the PriMatrix product lines and VolTAC create a comprehensive portfolio of Smart Solutions for Serious Wounds™ within the outpatient setting.